A 1-Year Open-Label Trial of Olanzapine in School-Age Children with Schizophrenia

Abstract

Olanzapine appears useful in the treatment of childhood-onset schizophrenia, although there may be a delayed onset of benefit for anxiety and negative symptoms. Weight gain is problematic, but the emergence of dyskinesias may be rare. Additional controlled trials are indicated.